The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.


Updates from The Motley Fool

Latest updates on Biogen from Fool.com.  The Fool has written over 600 articles on Biogen.
Better Buy: Biogen Inc. vs. Amgen

Biogen and Amgen have been two of the best performing biotechs for a decade. But one stock clearl...

Biogen's $1 Billion Bet on Ionis

Biogen announced it would pay nearly $1 billion for expanded access to Ionis’ pipeline. Was it wo...

Is Biogen Inc. a Buy?

Biogen's stock has had an awful 2018 so far. Is this top biotech now an incredible bargain?

Is Biogen Inc. a Buy?

The biotech has a lot of promise -- but some big risks.



Stock Performance

View Interactive BIIB Charts
Sponsored by

Key Data Points

Primary metrics and data points about Biogen.
Current Price: $358.51
Prev Close: $354.98
Open: $353.81
Bid: $358.25
Ask: $359.88
Day's Range: $350.28 - $358.75
52wk Range: $249.17 - $370.57
Volume: 1,375,725
Avg Vol 1,910,512
Market Cap: $76B
P/E (ttm): 25.36
EPS (ttm): $14.00
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Biogen.
CAPS Rating 5 out of 5
 
1001 Outperform
68 Underperform
CAPS All Stars
 
262 Outperform
11 Underperform

How do you think Biogen will perform against the market?



You pick for Biogen is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Michel Vounatsos, CEO

61% Approve

Based on 66 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Biogen.

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers